No files uploaded.
Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it intends to expand the scope of its sponsored research in Nigeria to include neurological conditions, including Post-Traumatic Stress Disorder (PTSD). CBIS and its research collaborator are currently investigating the potential beneficial effects of cannabidiol on oro-bucco-lingual dyskinesias, oxidative stress, and psychosis using animal studies and a clinical trial.
See the full press release here;
Attending the GHC Summit is how I got involved with iCannabinoid. I had just finished my Masters thesis about prescription drug abuse and misuse and the rest is history.
The Company is in the process of getting a third-party, independent valuation to establish the value of its CBN patent for the Canadian, U.S.,...The Company is in the process of getting a third-party, independent valuation to establish the value of its CBN patent for the Canadian, U.S., European, and global markets for the purpose of licensing other organizations to develop and sell CBN product lines under the protection of the Company’s U.S. patent.
For full article
www.otcmarkets.com/stock/CBIS/news/story Show more